FilingSEC EDGAR6-K
Kazia Therapeutics Secures $2 Million Milestone Payment Following Paxalisib Clinical Progress
· SEC accepted
StagePhase 1b/2a
Filing content
Kazia Therapeutics will receive a $2 million milestone payment as Sovargen has dosed the first patient in a Phase 1b/2a clinical trial of paxalisib.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…